Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illumina, Inc. (ILMN) vs VNET Group Inc (VNET) Price & Performance

Illumina, Inc.Trade
VNET Group IncTrade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs VNET Group Inc — how do they compare? Illumina, Inc. trades at $264.24 (market cap $40.43B), while VNET Group Inc trades at $5.26 (market cap $1.53B). The key difference: Illumina, Inc. is far larger — about 26.4× VNET Group Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and VNET Group Inc for 16 Days on average.

ILMNVNET
Market Cap
$40.43B$1.53B
Volume
2,948,6263,847,582
Sector
HealthTechnology
52-Week High
$293.69$14.03
52-Week Low
$91.00$5.13
Typical Hold Time
83 Days16 Days
Enterprise Value
$41.79B$5.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.

The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.

VNET Group Inc

VNET trades at $5.39, near a 52-week low with a bearish technical signal. The company reported a net loss of $256.77 million in 2025, with revenue of $9.95 billion, and negative profit margins. Recent news highlights a strategic investment closing and volatile options activity. Cash flow remains positive due to financing activities, but high leverage and negative earnings pose challenges.

Outlook is mixed: analyst consensus is moderately bullish (62.5% buy ratings), but fundamentals show persistent losses and high debt. Key risks include execution on AI infrastructure demand and balance sheet strain. The stock's appeal hinges on turnaround execution amid competitive and macroeconomic pressures.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ILMN
96% Buy4% Sell
Avg holding period · 83 Days
VNET

No sentiment data available yet.

Top news

Latest headlines on both assets

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN →

About VNET Group Inc

VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.

Read more on VNET →